RxDoctor Payments Data

David Eisinger, MD

Family Medicine · Kalamazoo, MINPI 1780036459

Payments from drug & device makers

$1,979in general payments, 2019–2025

Across 98 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • Pfizer$172
  • Boehringer Ingelheim$130
  • Amgen$121
  • Abbott$115
  • AstraZeneca$113
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$1,979100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,979 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$25,318
Medicare patients
115
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$75,002
TrulicityDulaglutide70$72,142
JardianceEmpagliflozin61$69,943
MounjaroTirzepatide38$37,974
FarxigaDapagliflozin Propanediol44$28,784
OzempicSemaglutide19$24,909
MyrbetriqMirabegron13$14,812
Tresiba Flextouch U-200Insulin Degludec14$13,673
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,911
Atorvastatin Calcium501$7,866
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$7,437
SymbicortBudesonide/Formoterol Fumarate21$5,856
Breo ElliptaFluticasone/Vilanterol12$4,409
Qvar RedihalerBeclomethasone Dipropionate12$4,021
Levothyroxine Sodium208$2,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$107$110,116108 claims
PfizerEliquis$172$75,00277 claims
Boehringer IngelheimJardiance$130$69,94361 claims
AstraZenecaFarxiga, Symbicort$113$34,64065 claims
Novo NordiskOzempic$293$24,90919 claims
GSKBreo Ellipta$101$4,40912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →